10-Q: PepGen Inc. Reports Q1 2025 Financial Results, Provides Clinical Program Updates

PepGen Inc. announces its Q1 2025 financial results, highlighting increased R&D spending and providing updates on its PGN-EDO51 and PGN-EDODM1 clinical programs.

Summary

• PepGen Inc. reported a net loss of $30.2 million for the three months ended March 31, 2025, compared to a net loss of $18.0 million for the same period in 2024.
• Research and development expenses increased to $25.4 million from $14.7 million year-over-year, driven by higher manufacturing and personnel-related costs.
• General and administrative expenses rose to $5.9 million from $5.1 million, primarily due to increased personnel costs.
• As of March 31, 2025, PepGen had cash, cash equivalents, and marketable securities totaling $97.8 million.
• The company believes its current resources will fund operations for at least the next 12 months.
• PepGen is advancing clinical programs for PGN-EDO51 in Duchenne muscular dystrophy (DMD) and PGN-EDODM1 in myotonic dystrophy type 1 (DM1).
• A Phase 2 CONNECT1 study of PGN-EDO51 is ongoing in Canada, with initial data from the 5 mg/kg dose cohort showing promising early exon skipping and dystrophin production.
• Health Canada has requested additional information before allowing further dose escalation or enrollment in the CONNECT1 study.
• A Phase 2 CONNECT2 study of PGN-EDO51 is voluntarily paused pending review of results from the 10 mg/kg cohort in the CONNECT1 study.
• A Phase 1 FREEDOM study of PGN-EDODM1 is ongoing, with initial data from the 5 mg/kg and 10 mg/kg dose cohorts showing a favorable emerging safety profile and robust splicing correction.
• A Phase 2 FREEDOM2 study of PGN-EDODM1 is open in Canada and the U.K., assessing safety, tolerability, splicing correction, and functional outcome measures.
• PepGen is evaluating EDO candidates for additional DMD sub-populations and has initiated research efforts for other neuromuscular and neurologic disorders.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive updates on clinical trial progress and a belief in sufficient funding for the next 12 months, the increased net loss and regulatory hurdles create uncertainty.

Positives

• The company believes its current cash, cash equivalents, and marketable securities will be sufficient to fund its currently planned operations for at least the next 12 months.
• Initial data from the CONNECT1 study showed promising early exon skipping and dystrophin production at the 5 mg/kg dose.
• Initial data from the FREEDOM study showed a favorable safety profile and robust splicing correction at the 5 mg/kg and 10 mg/kg doses.
• The FDA has granted both orphan drug designation and Fast Track designation for PGN-EDODM1 for the treatment of DM1.

Negatives

• The company reported a net loss of $30.2 million for the three months ended March 31, 2025.
• Health Canada has requested additional information before allowing further dose escalation or enrollment in the CONNECT1 study.
• The CONNECT2 study is voluntarily paused pending review of results from the 10 mg/kg cohort in the CONNECT1 study.

Risks

• The company has incurred significant losses since its inception and expects to incur losses for the foreseeable future.
• The company will need to raise substantial additional funding, and if unable to do so, it could be forced to delay, scale back, or discontinue its product development programs or future commercialization efforts.
• The company is early in its development efforts, and it will be years before it commercializes a product candidate, if ever.
• The company's business is highly dependent on the clinical advancement of its programs and modalities and is especially dependent on the success of its lead product candidates, PGN-EDO51 and PGN-EDODM1.
• Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical and clinical studies are not necessarily predictive of the results of later preclinical studies and any clinical trials of the company's product candidates.
• Substantial delays in the commencement, enrollment or completion of the company's clinical trials and advancement of its clinical trials, or failure to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, could prevent the company from commercializing product candidates it determines to develop on a timely basis, if at all.
• The company relies, and expects to continue to rely, on third parties to conduct some or all aspects of its product manufacturing, research, preclinical and clinical testing, and these third parties may not perform satisfactorily.
• The company faces significant competition, and if its competitors develop technologies or product candidates more rapidly than it does or their technologies or product candidates are more effective or have more favorable safety or tolerability profiles, its business and its ability to develop and successfully commercialize products may be adversely affected.
• If the company is unable to obtain and maintain patent protection for its Enhanced Delivery Oligonucleotide platform, therapeutic development candidates or programs and/or other proprietary technologies it develops, or if the scope of the patent protection obtained is not sufficiently broad, its competitors could develop and commercialize products and technology similar or identical to ours, and its ability to successfully commercialize its therapeutic product candidates or programs and other proprietary technologies it may develop may be adversely affected.
• The company expects to expand its headcount over time to support its development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, it may encounter difficulties in managing its growth, which could disrupt its operations.
• The company's future success depends on its ability to retain key executives and to attract, retain and motivate qualified personnel.
• The price of the company's common stock is volatile and fluctuates substantially, which could result in substantial losses for holders of its common stock.

Future Outlook

PepGen believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund its currently planned operations for at least the next 12 months. The company expects expenses and operating losses to continue as it conducts ongoing preclinical studies and current and planned clinical trials.

Management Comments

• Based on the totality of data in both the 5 mg/kg cohort and the ongoing 10 mg/kg cohort in the CONNECT1 trial as of January 23, 2025, we believe PGN-EDO51 has a favorable emerging safety profile.

Industry Context

PepGen is operating in a competitive landscape with other companies developing therapies for DMD and DM1, including gene therapies, exon-skipping drugs, and other novel approaches. The company's success will depend on its ability to differentiate its product candidates and demonstrate superior safety and efficacy.

Comparison to Industry Standards

• Sarepta Therapeutics, Inc. discontinued its SRP-5051 peptide-linked phosphorodiamidate morpholino (PMO) development program, based on the risk-benefit of the program, including some patients experiencing hypomagnesemia even after treatment with SRP-5051 was discontinued, feedback from the FDA, and the evolving therapeutic landscape for DMD.
• The FDA has approved at least four drugs based on their minimal dystrophin production, and it is PepGen's belief that they may be able to pursue an accelerated approval pathway for PGN-EDO51 on that same basis, assuming they continue to see increases in exon skipping and dystrophin production with higher doses and a longer treatment period.
• It was reported in May 2024 that the Phase 3, confirmatory study of VILTEPSO failed to meet the primary endpoint, Time to Stand from Supine, measured as velocity rise per second.
• ELEVIDYS (SRP-9001), which was approved in June 2023 for treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the DMD gene.
• In June 2024, the FDA granted approval of an expansion to the labeled indication for ELEVIDYS to include individuals with DMD with a confirmed mutation in the DMD gene who are at least 4 years of age, granting traditional approval for ambulatory patients and accelerated approval for non-ambulatory patients.

Related Party Transactions

• In 2024, one member of the Company's board of directors, Dr. Christopher Ashton, was employed by Oxford Science Enterprises, or OSE, which is an affiliate of OUI.
• Two members of the Company's board of directors, Dr. Joshua Resnick and Habib Dable, are affiliated with RA Capital Management, L.P., or RA Capital.

Stakeholder Impact

• Shareholders: The increased net loss and stock price volatility could negatively impact shareholder value.
• Patients: Clinical trial delays and regulatory hurdles could delay the availability of potential new treatments.
• Employees: The company's ability to attract and retain qualified personnel is critical to its success.
• Collaborators: The company's ability to manage its relationships with third-party manufacturers and CROs is essential for its development programs.

Next Steps

• Report initial safety, exon skipping and dystrophin production data from the 10 mg/kg cohort of the CONNECT1 trial by the end of the third quarter of 2025.
• Report data from the 15 mg/kg cohort of the FREEDOM study in the second half of 2025.
• Report data from the 5 mg/kg dose cohort of the FREEDOM2 study in the first quarter of 2026.
• Work with Health Canada to address its questions regarding the CONNECT1 study.
• Work with the FDA to address its questions regarding the CONNECT2 study.

Key Dates

Keywords

PepGen, PGN-EDO51, PGN-EDODM1, Duchenne muscular dystrophy, Myotonic dystrophy type 1, Clinical trials, Financial results, Oligonucleotide therapeutics, Biotechnology, R&D